

Docket No. 240988US0CIP



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tony MARCEL, et al.

SERIAL NO: 10/024,535

GAU: 1647

FILED: December 21, 2001

EXAMINER: S. Wegert

FOR: THERAPEUTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMPAIRED INTERPERSONAL AND BEHAVIORAL DISORDERS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Thomas M. Cunningham
Registration No. 45,394

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
240988US0CIPSERIAL NO.
10/024,535

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Tony MARCEL, et al.FILING DATE
December 21, 2001GROUP
1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	"Diagnostic and Statistical Manual of Mental Disorders", The American Psychiatric Association (author), 4 th Edition				
	AX	Fasano A., "Innovative strategies for the oral delivery of drugs and peptides", Trends Biotechnol., 1998 Apr; 16(4):152-7 (Abstract only).				
	AY	Pontiroli AE., "Peptide hormones: Review of current and emerging uses by nasal delivery", Adv Drug Deliv Rev. 1998 Jan 5;29(1-2):81-87 (Abstract only).				
	AZ	Leopold CS., "[Targeted delivery] in the gastrointestinal tract", Med Klin (Munich). 1999 Feb 15;94 Suppl 1:6-11 (Abstract only).				<input checked="" type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 240988US0CIP		SERIAL NO. 10/024,535	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Tony MARCEL, et al.			
				FILING DATE December 21, 2001		GROUP 1647	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAA	Rougeot C., et al., "Sialorphan, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.", Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8549-54. Epub 2003 June 30.					
	AAB	Messaoudi M., et al., "The endogenous androgen-regulated sialorphan modulates male rat sexual behavior.", Horm Behav. 2004 Dec;46(5):684-91.					
	AAC	A. Argiolas, "Neuropeptides and sexual behaviour", Neuroscience and Biobehavioral Reviews 23 (1999) 1127-1142.					
	AAD	M. Messaoudi, et al., "The endogenous androgen-regulated sialorphan modulates male rat sexual behavior", Hormones and Behavior 46 (2004) 684-691.					
	AAE	Catherine Rougeot, et al., "Sialorphan, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity", PNAS, July 8, 2003, vol. 100, no. 14, pp. 8549-8554.					
	AAF						
	AAG						
	AAH						
	AAI						
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner						Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							